Prothymosin α-A novel endogenous neuroprotective polypeptide against ischemic damages

Neuropeptides in Neuroprotection and Neuroregeneration

Volumn , Issue , 2012, Pages 127-148

  Ueda, Hiroshi ^a   Matsunaga, Hayato ^a   Halder, Sebok K ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877755197     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12279     Document Type: Chapter

References (103)

1. Adachi, K., Fujita, Y., Morizane, C., Akaike, A., Ueda, M., Satoh, M., et al. 1998. Inhibition of NMDA receptors and nitric oxide synthase reduces ischemic injury of the retina. Eur J Pharmacol 350: 53-7.
2. Ando, A., Yonezawa, K., Gout, I., Nakata, T., Ueda, H., Hara, K., et al. 1994. A complex of GRB2-dynamin binds to tyrosine-phosphorylated insulin receptor substrate-1 after insulin treatment. EMBO J 13: 3033-8.
3. Ashkenazi, A., and Dixit, V. M. 1998. Death receptors: signaling and modulation. Science 281: 1305-8.
4. Ay, H., Ay, I., Koroshetz, W. J., and Finklestein, S. P. 1999. Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc Dis 9: 131-5.
5. Ay, I., Sugimori, H., and Finklestein, S. P. 2001. Intravenous basic fibroblast growth factor (bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression in the ischemic brain following middle cerebral artery occlusion in rats. Brain Res Mol Brain Res 87: 71-80.
6. Baker, S. J., and Reddy, E. P. 1998. Modulation of life and death by the TNF receptor superfamily. Oncogene 17: 3261-70.
7. Belzacq, A. S., Vieira, H. L., Verrier, F., Vandecasteele, G., Cohen, I., Prevost, M. C., et al. 2003. Bcl-2 and Bax modulate adenine nucleotide translocase activity. Cancer Res 63: 541-6.
8. Bianco, N. R., and Montano, M. M. 2002. Regulation of prothymosin alpha by estrogen receptor alpha: molecular mechanisms and relevance in estrogen-mediated breast cell growth. Oncogene 21: 5233-44.
9. Bogousslavsky, J., Victor, S. J., Salinas, E. O., Pallay, A., Donnan, G. A., Fieschi, C., et al. 2002. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis 14: 239-51.
10. Borsello, T., Clarke, P. G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., et al. 2003. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 9: 1180-6.
11. Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., et al. 2000. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97: 10526-31.
12. Burkhalter, J., Fiumelli, H., Allaman, I., Chatton, J. Y., and Martin, J. L. 2003. Brain-derived neurotrophic factor stimulates energy metabolism in developing cortical neurons. J Neurosci 23: 8212-20.
13. Chen, G., and Goeddel, D. V. 2002. TNF-R1 signaling: a beautiful pathway. Science 296: 1634-5.
14. Cheng, Y., Deshmukh, M., D’Costa, A., Demaro, J. A., Gidday, J. M., Shah, A., et al. 1998. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest 101: 1992-9.
15. Clinton, M., Graeve, L., el-Dorry, H., Rodriguez-Boulan, E., and Horecker, B. L. 1991. Evidence for nuclear targeting of prothymosin and parathymosin synthesized in situ. Proc Natl Acad Sci U S A 88: 6608-12.
16. Cory, S., Huang, D. C., and Adams, J. M. 2003. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-607.
17. Danial, N. N., and Korsmeyer, S. J. 2004. Cell death: critical control points. Cell 116: 205-19.
18. Danton, G. H., and Dietrich, W. D. 2003. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 62: 127-36.
19. Diaz-Horta, O., Kamagate, A., Herchuelz, A., and Van Eylen, F. 2002. Na/Ca exchanger overexpression induces endoplasmic reticulum-related apoptosis and caspase-12 activation in insulin-releasing BRIN-BD11 cells. Diabetes 51: 1815-24.
20. Dirnagl, U., Iadecola, C., and Moskowitz, M. A. 1999. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22: 391-7.
21. Ducluzeau, P. H., Fletcher, L. M., Vidal, H., Laville, M., and Tavare, J. M. 2002. Molecular mechanisms of insulin-stimulated glucose uptake in adipocytes. Diabetes Metab 28: 85-92.
22. Edinger, A. L., and Thompson, C. B. 2004. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16: 663-9.
23. Eguchi, Y., Shimizu, S., and Tsujimoto, Y. 1997. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 57: 1835-40.
24. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. 1998. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391: 43-50.
25. Feigin, V. L. 2005. Stroke epidemiology in the depeloping world. Lancet 365: 2160-1.
26. Ferri, K. F., and Kroemer, G. 2001. Organelle-specific initiation of cell death pathways. Nat Cell Biol 3: E255-63.
27. Fujita, R., and Ueda, H. 2003a. Protein kinase C-mediated cell death mode switch induced by high glucose. Cell Death Differ 10: 1336-47.
28. Fujita, R., and Ueda, H. 2003b. Protein kinase C-mediated necrosis-apoptosis switch of cortical neurons by conditioned medium factors secreted under the serum-free stress. Cell Death Differ 10: 782-90.
29. Fujita, R., and Ueda, H. 2007. Prothymosin-alpha1 prevents necrosis and apoptosis following stroke. Cell Death Differ 14: 1839-42.
30. Fujita, R., Ueda, M., Fujiwara, K., and Ueda, H. 2009. Prothymosin-alpha plays a defensive role in retinal ischemia through necrosis and apoptosis inhibition. Cell Death Differ 16: 349-58.
31. Fujita, R., Yoshida, A., Mizuno, K., and Ueda, H. 2001. Cell density-dependent death mode switch of cultured cortical neurons under serum-free starvation stress. Cell Mol Neurobiol 21: 317-24.
32. Gast, K., Damaschun, H., Eckert, K., Schulze-Forster, K., Maurer, H. R., Muller-Frohne, M., et al. 1995. Prothymosin alpha: a biologically active protein with random coil conformation. Biochemistry 34: 13211-18.
33. Gilgun-Sherki, Y., Rosenbaum, Z., Melamed, E., and Offen, D. 2002. Antioxidant therapy in acute central nervous system injury: current state. Pharmacol Rev 54: 271-84.
34. Gladstone, D. J., Black, S. E., and Hakim, A. M. 2002. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33: 2123-36.
35. Gomez-Marquez, J. 2007. Function of prothymosin alpha in chromatin decondensation and expression of thymosin beta-4 linked to angiogenesis and synaptic plasticity. Ann N Y Acad Sci 1112: 201-9.
36. Gozuacik, D., and Kimchi, A. 2004. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23: 2891-906.
37. Gozuacik, D., and Kimchi, A. 2007. Autophagy and cell death. Curr Top Dev Biol 78: 217-45.
38. Haritos, A. A., Blacher, R., Stein, S., Caldarella, J., and Horecker, B. L. 1985. Primary structure of rat thymus prothymosin alpha. Proc Natl Acad Sci U S A 82: 343-6.
39. Hefti, F. 1986. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 6: 2155-62.
40. Henderson, C. E., Camu, W., Mettling, C., Gouin, A., Poulsen, K., Karihaloo, M., et al. 1993. Neurotrophins promote motor neuron survival and are present in embryonic limb bud. Nature 363: 266-70.
41. Hossmann, K. A. 2006. Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol 26: 1055-81.
42. Huang, E. J., and Reichardt, L. F. 2001. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677-736.
43. Jiang, X., Kim, H. E., Shu, H., Zhao, Y., Zhang, H., Kofron, J., et al. 2003. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 299: 223-6.
44. Kaplan, D. R., and Miller, F. D. 2000. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10: 381-91.
45. Kim, Y. H., and Koh, J. Y. 2002. The role of NADPH oxidase and neuronal nitric oxide synthase in zinc-induced poly(ADP-ribose) polymerase activation and cell death in cortical culture. Exp Neurol 177: 407-18.
46. Kroemer, G. 1997. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3: 614-20.
47. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., et al. 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 16: 3-11.
48. Lai, A. Y., and Todd, K. G. 2006. Microglia in cerebral ischemia: molecular actions and interactions. Can J Physiol Pharmacol 84: 49-59.
49. Leist, M., Single, B., Castoldi, A. F., Kuhnle, S., and Nicotera, P. 1997. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185: 1481-6.
50. Levine, B., and Yuan, J. 2005. Autophagy in cell death: an innocent convict?. J Clin Invest 115: 2679-88.
51. Li, L. Y., Luo, X., and Wang, X. 2001. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412: 95-9.
52. Lin, C. H., Cheng, F. C., Lu, Y. Z., Chu, L. F., Wang, C. H., and Hsueh, C. M. 2006. Protection of ischemic brain cells is dependent on astrocyte-derived growth factors and their receptors. Exp Neurol 201: 225-33.
53. Lipton, P. 1999. Ischemic cell death in brain neurons. Physiol Rev 79: 1431-568.
54. Liu, W., Hendren, J., Qin, X. J., and Liu, K. J. 2009. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke 40: 2526-31.
55. Malis, C. D., and Bonventre, J. V. 1988. Susceptibility of mitochondrial membranes to calcium and reactive oxygen species: implications for ischemic and toxic tissue damage. Prog Clin Biol Res 282: 235-59.
56. Martini, P. G., Delage-Mourroux, R., Kraichely, D. M., and Katzenellenbogen, B. S. 2000. Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity. Mol Cell Biol 20: 6224-32.
57. Martinou, J. C., and Green, D. R. 2001. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2: 63-7.
58. Matsunaga, H., and Ueda, H. 2006a. Evidence for serum-deprivation-induced co-release of FGF-1 and S100A13 from astrocytes. Neurochem Int 49: 294-303.
59. 2+ channel activity regulates the interaction between FGF-1 and S100A13 for stress-induced non-vesicular release. Cell Mol Neurobiol 26: 237: 46.
60. Matsunaga, H., and Ueda, H. 2010. Stress-induced non-vesicular extracellular release of prothymosin-α initiated by an interaction with S100A13, and its blockade by caspase-3 cleavage. Cell Death Differ 17: 1760-72.
61. Mosoian, A., Teixeira, A., Burns, C. S., Sander, L. E., Gusella, L. G., He, C., et al. 2010. Prothymosin-α inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. Proc Natl Acad Sci U S A 107: 10178-83.
62. Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B. A., et al. 2000. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403: 98-103.
63. Nakajima, K., and Kohsaka, S. 2004. Microglia: neuroprotective and neurotrophic cells in the central nervous system. Curr Drug Targets Cardiovasc Haematol Disord 4: 65-84.
64. Niizuma, K., Yoshioka, K., Chen, H., Kim, G. S., Jung, J. E. Katsu, et al. 2010. Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia. Biochim Biophys Acta 1802: 92-9.
65. Nishitoh, H., Matsuzawa, A., Tobiume, K., Saegusa, K., Takeda, K., Inoue, K., et al. 2002. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 16: 1345-55.
66. Olson, L., Nordberg, A., von Holst, H., Backman, L., Ebendal, T., Alafuzoff, I., et al. 1992. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 4: 79-95.
67. Patapoutian, A., and Reichardt, L. F. 2001. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 11: 272-80.
68. Paul, R., Zhang, Z. G., Eliceiri, B. P., Jiang, Q., Boccia, A. D., Zhang, R. L., et al. 2001. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med 7: 222-7.
69. Pineiro, A., Begona Bugia, M., Pilar Arias, M., Cordero, O. J., and Nogueira, M. 2001. Identification of receptors for prothymosin alpha on human lymphocytes. Biol Chem 382: 1473-82.
70. Pineiro, A., Cordero, O. J., and Nogueira, M. 2000. Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides 21: 1433-46.
71. Sakahira, H., Enari, M., and Nagata, S. 1998. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391: 96-9.
72. Salgado, F. J., Pineiro, A., Canda-Sanchez, A., Lojo, J., and Nogueira, M. 2005. Prothymosin alpha-receptor associates with lipid rafts in PHA-stimulated lymphocytes. Mol Membr Biol 22: 163-76.
73. Segade, F., and Gomez-Marquez, J. 1999. Prothymosin alpha. Int J Biochem Cell Biol 31: 1243-8.
74. Shimizu, S., Konishi, A., Kodama, T., and Tsujimoto, Y. 2000. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc Natl Acad Sci U S A 97: 3100-5.
75. Sims, N. R., and Muyderman, H. 2010. Mitochondria, oxidative metabolism and cell death in stroke. Biochim Biophys Acta 1802: 80-91.
76. Sofroniew, M. V., Howe, C. L., and Mobley, W. C. 2001. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24: 1217-81.
77. Sprick, M. R., and Walczak, H. 2004. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 1644: 125-32.
78. Swanson, R. A., Ying, W., and Kauppinen, T. M. 2004. Astrocyte influences on ischemic neuronal death. Curr Mol Med 4: 193-205.
79. Szeto, H. H. 2006. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J 8: E521-31.
80. The BDNF Study Group (Phase III). 1999. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 52: 1427-33.
81. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 1995. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581-7.
82. Tsujimoto, Y. 2002. Bcl-2 family of proteins: life-or-death switch in mitochondria. Biosci Rep 22: 47-58.
83. Tsukahara, T., Yonekawa, Y., Tanaka, K., Ohara, O., Wantanabe, S., Kimura, T., et al. 1994. The role of brain-derived neurotrophic factor in transient forebrain ischemia in the rat brain. Neurosurgery 34: 323-31.
84. Turner, M. R., Parton, M. J., and Leigh, P. N. 2001. Clinical trials in ALS: an overview. Semin Neurol 21: 167-75.
85. Ueda, H. 2009. Prothymosin alpha and cell death mode switch, a novel target for the prevention of cerebral ischemia-induced damage. Pharmacol Ther 123: 323-33.
86. Ueda, H., and Fujita, R. 2004. Cell death mode switch from necrosis to apoptosis in brain. Biol Pharm Bull 27: 950-5.
87. Ueda, M., Fujita, R., Koji, T., and Ueda, H. 2004. The cognition-enhancer nefiracetam inhibits both necrosis and apoptosis in retinal ischemic models in vitro and in vivo. J Pharmacol Exp Ther 309: 200-7.
88. Ueda, H., Fujita, R., Yoshida, A., Matsunaga, H., and Ueda, M. 2007. Identification of prothymosin-alpha1, the necrosis-apoptosis switch molecule in cortical neuronal cultures. J Cell Biol 176: 853-62.
89. Ueda, H., Matsunaga, H., Uchida, H., and Ueda, M. 2010. Prothymosin α as robustness molecule against ischemic stress to brain and retina. Ann NY Acad Sci 1194: 20-6.
90. Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., et al. 2000. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287: 664-6.
91. Vande Velde, C., Cizeau, J., Dubik, D., Alimonti, J., Brown, T., Israels, S., et al. 2000. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 20: 5454-68.
92. Walczak, H., and Krammer, P. H. 2000. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256: 58-66.
93. Watson, R. T., and Pessin, J. E. 2001. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res 56: 175-93.
94. Watson, R. T., and Pessin, J. E. 2006. Bridging the GAP between insulin signaling and GLUT4 translocation. Trends Biochem Sci 31: 215-22.
95. White, B. C., Sullivan, J. M., DeGracia, D. J., O’Neil, B. J., Neumar, R. W., Grossman, et al. 2000. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci 179: 1-33.
96. Williams, L. R., Varon, S., Peterson, G. M., Wictorin, K., Fischer, W., Bjorklund, A., et al. 1986. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A 83: 9231-5.
97. Wu, D. 2005. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx 2: 120-8.
98. Yamashita, T., Sawamoto, K., Suzuki, S., Suzuki, N., Adachi, K., Kawase, T., et al. 2005. Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J Neurochem 94: 459-68.
99. Yoneda, T., Imaizumi, K., Oono, K., Yui, D., Gomi, F., Katayama, T., et al. 2001. Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress. J Biol Chem 276: 13935-40.
100. Yoshida, T., Tomioka, I., Nagahara, T., Holyst, T., Sawada, M., Hayes, P., et al. 2004. Baxinhibiting peptide derived from mouse and rat Ku70. Biochem Biophys Res Commun 321: 961-6.
101. Zamzami, N., and Kroemer, G. 2001. The mitochondrion in apoptosis: how Pandora’s box opens. Nat Rev Mol Cell Biol 2: 67-71.
102. Zha, J., Harada, H., Yang, E., Jockel, J., and Korsmeyer, S. J. 1996. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCLX(L). Cell 87: 619-28.
103. Zhao, Y., and Rempe, D. A. 2010. Targeting astrocytes for stroke therapy. Neurotherapeutics 7: 439-51.